Relay Therapeutics Inc. (NASDAQ: RLAY) Stock Has Dropped -31.58% Over The Month – Is There Room For Growth? – Marketing Sentinel
Home  »  Business   »  Relay Therapeutics Inc. (NASDAQ: RLAY) Stock Has D...

Relay Therapeutics Inc. (NASDAQ: RLAY) Stock Has Dropped -31.58% Over The Month – Is There Room For Growth?

Relay Therapeutics Inc. (NASDAQ:RLAY)’s traded shares stood at 0.62 million during the last session. At the close of trading, the stock’s price was $17.33, to imply an increase of 3.46% or $0.58 in intraday trading. The RLAY share’s 52-week high remains $38.60, putting it -122.74% down since that peak but still an impressive 17.08% since price per share fell to its 52-week low of $14.37. The company has a valuation of $1.87B, with average of 732.51K shares over the past 3 months.

Analysts have given a consensus recommendation of a Buy for Relay Therapeutics Inc. (RLAY), translating to a mean rating of 1.70. Of 8 analyst(s) looking at the stock, 0 analyst(s) give RLAY a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 8 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.63.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Relay Therapeutics Inc. (NASDAQ:RLAY) trade information

After registering a 3.46% upside in the last session, Relay Therapeutics Inc. (RLAY) has traded red over the past five days. The stock hit a weekly high of 18.11 this Friday, 05/27/22, jumping 3.46% in its intraday price action. The 5-day price performance for the stock is -0.06%, and -31.58% over 30 days. With these gigs, the year-to-date price performance is -43.57%.

Analysts on Wall Street suggest a consensus price target of $43.86, implying an increase of 60.49% to the stock’s current value. The extremes give us $35.00 and $47.00 for target low and target high price respectively. As such, RLAY has been trading -171.21% off suggested target high and -101.96% from its likely low.

Relay Therapeutics Inc. (RLAY) estimates and forecasts

Looking at statistics comparing Relay Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. Relay Therapeutics Inc. (RLAY) shares are -41.87% down over the last 6 months, with its year-to-date growth rate lower than industry average at 7.04% against 10.60%. Revenue is forecast to grow 70.00% this quarter before falling -1.50% for the next one. The rating firms project that company’s revenue will grow 218.30% compared to the previous financial year.

Revenue forecast for the current quarter as set by 6 analysts is $2.25 million. Meanwhile, for the quarter ending Sep 2022, a total of 6 analyst(s) estimate revenue growth to $170k.

RLAY Dividends

Relay Therapeutics Inc. has its next earnings report out between March 23 and March 28. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Relay Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Relay Therapeutics Inc. (NASDAQ:RLAY)’s Major holders

Relay Therapeutics Inc. insiders hold 3.43% of total outstanding shares, with institutional holders owning 102.32% of the shares at 105.95% float percentage. In total, 102.32% institutions holds shares in the company, led by SB Investment Advisers (UK) LTD. As of Dec 30, 2021, the company held over 27.9 million shares (or 25.68% of shares), all amounting to roughly $856.96 million.

The next major institution holding the largest number of shares is FMR, LLC with 16.21 million shares, or about 14.92% of shares outstanding. As of the market price on Dec 30, 2021, these shares were worth $497.7 million.

We also have Fidelity OTC Portfolio and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF as the top two Mutual Funds with the largest holdings of the Relay Therapeutics Inc. (RLAY) shares. Going by data provided on Feb 27, 2022, Fidelity OTC Portfolio holds roughly 2.76 million shares. This is just over 2.54% of the total shares, with a market valuation of $66.48 million. Data from the same date shows that the other fund manager holds a little less at 2.19 million, or 2.01% of the shares, all valued at about 48.38 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts